Long‐term outcome in patients with mantle cell lymphoma following high‐dose therapy and autologous stem cell transplantation

Abstract

AbstractBackgroundLong‐term clinical and molecular remissions in patients with mantle cell lymphoma (MCL) after autologous stem cell transplantation (ASCT) have been evaluated in only a few studies.Design and MethodsSixty‐five patients with MCL received ASCT (54 first‐line ASCT, 10 second‐line ASCT, and 1 third‐line ASCT). In the case of long‐term remission (≥5 years; n = 27), peripheral blood was tested for minimal residual disease (MRD) by t(11;14)‐ and IGH‐PCR at the last follow‐up.ResultsTen‐year overall survival (OS), progression‐free survival (PFS), and freedom from progression (FFP) after first‐line ASCT were 64%, 52%, and 59% versus after second‐line ASCT 50%, 20%, and 20%, respectively. Five‐year OS, PFS, and FFP for the first‐line cohort were 79%, 63%, and 69%, respectively. Five‐year OS, PFS, and FFP after second‐line ASCT were 60%, 30%, and 30%, respectively. Treatment‐related mortality (3 months after ASCT) was 1.5%. So far 26 patients developed sustained long‐term clinical and molecular complete remissions of up to 19 years following ASCT in first treatment line.ConclusionSustained long‐term clinical and molecular remissions are achievable following ASCT.